oxonic acid has been researched along with Colorectal Cancer in 159 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 9.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 9.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 9.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 9.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 9.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 9.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 9.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 9.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 9.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 9.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "This study attempted to determine the therapeutic dosage of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC)." | 9.17 | Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer. ( Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 9.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 9.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 9.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 9.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer." | 9.16 | A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG, 2012) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 9.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 9.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 9.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 9.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 9.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 9.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11." | 9.14 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. ( Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T, 2009) |
| " This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer." | 9.14 | Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. ( Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K, 2009) |
| "We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)." | 9.14 | Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010) |
| "A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer." | 9.14 | A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 9.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer." | 9.14 | Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 9.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| "To determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan plus S-1 in advanced colorectal cancer." | 9.12 | Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N, 2007) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 8.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 7.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 7.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-based chemotherapy." | 7.77 | Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. ( Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY, 2011) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 7.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 6.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 6.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 5.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 5.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 5.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer." | 5.27 | A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. ( Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y, 2018) |
| "Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan." | 5.22 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). ( Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A, 2016) |
| "Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients." | 5.22 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. ( Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K, 2016) |
| "A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer." | 5.22 | Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 5.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 5.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 5.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 5.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 5.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "Forty-two chemo-naive patients with metastatic colorectal cancer (mCRC) were planned to be enrolled and be treated with irinotecan 150 mg m(-2) followed by oxaliplatin 85 mg m(-2) on day 1 and S-1 80 mg m(-2) per day from day 1 to 14 every 3 weeks." | 5.17 | S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. ( Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A, 2013) |
| "We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC)." | 5.17 | Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. ( Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW, 2013) |
| "This study attempted to determine the therapeutic dosage of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC)." | 5.17 | Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer. ( Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T, 2013) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 5.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 5.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "Fluorouracil (5-FU) plus irinotecan combined with bevacizumab has significant activity in metastatic colorectal cancer (mCRC), but S-1 has become a substitute for continuous infusion of 5-FU and has a very low incidence of hand-foot syndrome." | 5.16 | Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T, 2012) |
| "In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI." | 5.16 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012) |
| "We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen) as a first-line treatment in patients with metastatic colorectal cancer." | 5.16 | A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG, 2012) |
| "The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.16 | Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. ( Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 5.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 5.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 5.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown survival benefits in patients with metastatic colorectal cancer (mCRC)." | 5.14 | A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. ( Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK, 2009) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 5.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 5.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11." | 5.14 | Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. ( Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T, 2009) |
| " This phase I study was performed to determine the recommended dosage (RD) of metronomic chemotherapy using oral fluoropyrimidine S-1 plus weekly irinotecan (CPT-11) in patients with previously untreated advanced or recurrent colorectal cancer." | 5.14 | Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. ( Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K, 2009) |
| "We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)." | 5.14 | Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010) |
| "A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer." | 5.14 | A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 5.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer." | 5.14 | Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010) |
| "A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 5.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| "To determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan plus S-1 in advanced colorectal cancer." | 5.12 | Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N, 2007) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 4.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Since its synthesis over 40 years ago, several studies including patients with colorectal cancer have shown that prolonged exposure to 5-fluorouracil (5-FU) is associated with better antitumor activity and decreased toxicity." | 4.82 | Practical considerations in the use of oral fluoropyrimidines. ( Hoff, PM, 2003) |
| "5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades." | 4.81 | Oral fluoropyrimidine treatment of colorectal cancer. ( Eng, C; Kindler, HL; Schilsky, RL, 2001) |
| "After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer." | 4.80 | Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999) |
| "Protracted intravenous infusions of fluorouracil (5-FU) in the treatment of colorectal cancer have been associated with a reduction in toxicity and enhanced clinical activity compared with bolus 5-FU schedules." | 4.80 | Oral fluoropoyrimidines. ( Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M, 1999) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 3.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "S-1, an oral 5-fluorouracil (5-FU)-based medicine that combines tegafur, gimeracil and oteracil potassium is commonly used as an adjuvant chemotherapeutic drug for the treatment of colorectal cancer." | 3.83 | Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy. ( Kokuryo, T; Nagino, M; Uehara, K; Yamaguchi, J; Yamauchi, K; Yokoyama, Y, 2016) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 3.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer." | 3.78 | Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. ( Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J, 2012) |
| "The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-based chemotherapy." | 3.77 | Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. ( Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY, 2011) |
| "Injectable combination chemotherapy with 5-fluorouracil (5-FU)/Leucovorin (LV), oxaliplatin (OHP), and irinotecan (CPT-11) has been a standard treatment for advanced colorectal cancer (CRC)." | 3.77 | [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer]. ( Matsueda, S; Sasaki, H; Tokunaga, Y, 2011) |
| "Chemotherapy with irinotecan (CPT-11) or oxaliplatin (l-OHP) in combination with infusional 5-fluorouracil (5-FU) and their cross-over as second-line therapies are standard treatments for metastatic colorectal cancer (MCRC)." | 3.75 | Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. ( Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2009) |
| "In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co." | 3.70 | Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999) |
| "Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated." | 3.01 | Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). ( Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M, 2021) |
| " We designed the study of XSLJZD combined with S-1 in the maintenance therapy of Stage III or IV GC and CRC, and hoped that this research program will go further and comprehensively evaluate its efficacy and safety." | 2.94 | Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma. ( Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ, 2020) |
| " The overall incidence of any Grade adverse events (AEs) were 91." | 2.87 | Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. ( Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018) |
| "Irinotecan (125 mg/m(2)) was administered as a 24-hour infusion on days 1 and 15, S-1 (80 mg/m(2)) was administered orally on days 1-14, and bevacizumab (5." | 2.80 | A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. ( Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A, 2015) |
| " The goal of this trial was to evaluate the efficacy of TSU-68 in combination with SOX." | 2.79 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. ( Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS, 2014) |
| " We conducted a phase I study to evaluate the safety and pharmacokinetic of TSU-68 when used with S-1 and oxaliplatin (SOX) in metastatic colorectal cancer (mCRC) patients." | 2.77 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. ( Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%." | 2.75 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. ( Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K, 2010) |
| "Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)." | 2.74 | A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009) |
| "S-1 showed clinical activity in colorectal cancer, and the preclinical data of S-1 with oxaliplatin showed synergistic activity in an animal model." | 2.74 | A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. ( Kang, EM; Kang, WK; Kim, HS; Lee, HY; Lee, J; Lee, Y; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE, 2009) |
| "The purpose of this study was to determine the optimal dose of oxaliplatin, when combined with a fixed dose of S-1 (40 mg/m twice daily on days 1-14) on a 3-week schedule, for patients with advanced and/or metastatic colorectal cancer." | 2.73 | Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. ( Cao, J; Li, J; Liu, Y; Lu, F; Yin, J; Zhu, X; Zuo, Y, 2008) |
| "Although the prognosis in patients with pancreatic cancer has been poor, we recently reported unusually high response rate and survival benefit of S-1 treatment in patients with pancreatic cancer." | 2.73 | High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "In total 47 patients with colorectal cancer were included." | 2.71 | EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. ( de Boer, RF; Duffaud, F; Fumoleau, P; Reinke, F; Roth, AD; Schellens, JH; Schöffski, P; Van den Brande, J; Vermorken, JB; Wanders, J; Weigang-Köhler, K, 2003) |
| " The pharmacokinetic profiles of the tegafur, CDHP, and oxonic acid constituents were characterized." | 2.71 | Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. ( Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G, 2004) |
| "Patients with advanced (stage IV) colorectal cancer were treated with S-1 twice daily based on the patient's body surface area (BSA; BSA < 1." | 2.71 | Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yang, D; Yochim, JM, 2005) |
| " Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128." | 2.69 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ( Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999) |
| " Odds ratio and hazard ratio of available outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were pooled for analysis." | 2.61 | Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis. ( Chen, J; Wang, J; Xu, T, 2019) |
| "This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer (CRC)." | 2.50 | Efficacy of S-1 in colorectal cancer. ( Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N, 2014) |
| "Case 1 of type 3 advanced gastric cancer underwent surgery after one week interval following oral administration of TS-1 at a daily dose of 80 mg/body for 2 weeks." | 2.43 | [Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1]. ( Koizumi, H; Nakamura, K; Nakane, Y; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Tanabe, S; Tsuchiya, K, 2005) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Among colorectal cancer patients with recurrent or metastatic sites, survival was significantly prolonged for a group undergoing LV/5-FU therapy based on biochemical modulation compared with a group receiving no chemotherapy (best supportive care)." | 2.41 | [Progress in chemotherapy for colorectal cancer]. ( Maeda, Y; Sasaki, T, 2000) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 1.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| " Clinically, metronomic S-1 dosing has been approved for the standard first- and second-line treatment of metastatic or advanced stage of colorectal (CRC)." | 1.46 | Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. ( Abu Lila, AS; Fukushima, M; Huang, CL; Ishida, T; Moriyoshi, N; Wada, H, 2017) |
| "We recently reported that combination therapy with metronomic S-1 dosing and oxaliplatin (l-OHP)-containing PEGylated liposomes improved antitumor activity in a murine colorectal tumor model." | 1.40 | Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome. ( Abu Lila, AS; Doi, Y; Ishida, T; Kiwada, H; Nagao, A; Nakamura, H, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| " The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed." | 1.40 | [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses]. ( Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H, 2014) |
| "The dosing regimen for 1 course was as follows: BV (7." | 1.40 | [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer]. ( Higashi, Y; Ishikawa, S; Maruo, H; Murakami, T; Nishiyama, R; Shoji, T; Suzuki, K; Taniguchi, M; Yamazaki, M, 2014) |
| " Two patients received only SOX as chemotherapy, while the others received SOX in combination with one of the three molecular-targeting agents, bevacizumab, cetuximab, and panitumumab." | 1.39 | Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "We recently proposed an S-1 combined with oxaliplatin (SOXL) regimen, a combination treatment consisting of oral metronomic S-1 dosing and intravenous administration of oxaliplatin (l-OHP) containing PEGylated liposomes, which showed potent antitumor activity in vivo." | 1.39 | Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application. ( Abu Lila, AS; Ishida, T; Kiwada, H; Nagao, A, 2013) |
| " Recently, we showed that the combination of oral metronomic S-1 dosing with oxaliplatin (l-OHP)-containing PEG-coated "neutral" liposomes exerted excellent antitumor activity." | 1.38 | Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? ( Abu Lila, AS; Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Okada, T, 2012) |
| " Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events." | 1.37 | Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011) |
| "The aim of this study is to identify colorectal cancer specific gene methylation determining chemosensitivity to S-1/CPT-11 therapy." | 1.36 | CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. ( Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K, 2010) |
| " However, many patients are often forced to give up long-term S-1 treatment owing to high incidence rates of adverse effects." | 1.36 | [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan]. ( Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010) |
| " To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model." | 1.36 | Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. ( Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T, 2010) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 1.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| "A total of 30 colorectal cancer patients treated with the fluoropyrimidine-based combination S-1, all of whom had stage IV disease, were studied." | 1.32 | Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. ( Danenberg, KD; Danenberg, PV; Hayashi, K; Kawakami, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yochim, JM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (3.77) | 18.2507 |
| 2000's | 48 (30.19) | 29.6817 |
| 2010's | 98 (61.64) | 24.3611 |
| 2020's | 7 (4.40) | 2.80 |
| Authors | Studies |
|---|---|
| Aisu, N | 1 |
| Yoshida, Y | 1 |
| Komono, A | 1 |
| Sakamoto, R | 1 |
| Kojima, D | 1 |
| Hasegawa, S | 1 |
| Nakamoto, Y | 1 |
| Noda, M | 1 |
| Mikami, R | 1 |
| Tokunaga, Y | 3 |
| Okumoto, T | 1 |
| Kawamura, T | 1 |
| Fujiwara, H | 1 |
| Doi, S | 1 |
| Tomita, N | 2 |
| Toriu, N | 1 |
| Sawa, N | 1 |
| Imafuku, A | 1 |
| Hasegawa, E | 1 |
| Sekine, A | 1 |
| Mizuno, H | 1 |
| Yamanouchi, M | 1 |
| Hiramatsu, R | 1 |
| Hayami, N | 1 |
| Hoshino, J | 1 |
| Kawada, M | 1 |
| Suwabe, T | 1 |
| Ohashi, K | 1 |
| Fujii, T | 1 |
| Ubara, Y | 1 |
| Hong, XC | 1 |
| Liang, QL | 1 |
| Luo, XB | 1 |
| Hu, KH | 1 |
| Yang, HX | 1 |
| Ou, WT | 1 |
| Zhang, HJ | 1 |
| Sadahiro, S | 2 |
| Suzuki, T | 4 |
| Okada, K | 2 |
| Saito, G | 2 |
| Miyakita, H | 1 |
| Ogimi, T | 1 |
| Chan, LF | 1 |
| Kamei, Y | 1 |
| Masuishi, T | 1 |
| Taniguchi, H | 3 |
| Komori, A | 2 |
| Mitani, S | 1 |
| Narita, Y | 2 |
| Kadowaki, S | 2 |
| Ura, T | 2 |
| Ando, M | 1 |
| Muro, K | 9 |
| Denda, T | 6 |
| Takashima, A | 1 |
| Gamoh, M | 4 |
| Iwanaga, I | 5 |
| Komatsu, Y | 13 |
| Takahashi, M | 3 |
| Nakamura, M | 6 |
| Ohori, H | 2 |
| Sakashita, A | 1 |
| Tsuda, M | 2 |
| Kobayashi, Y | 3 |
| Baba, H | 13 |
| Kotake, M | 2 |
| Ishioka, C | 4 |
| Yamada, Y | 11 |
| Sato, A | 5 |
| Yuki, S | 8 |
| Morita, S | 8 |
| Takahashi, S | 4 |
| Yamaguchi, T | 5 |
| Shimada, K | 8 |
| Nishizawa, Y | 1 |
| Haraguchi, N | 1 |
| Kim, H | 1 |
| Ide, Y | 1 |
| Nakata, K | 2 |
| Okamura, S | 1 |
| Kudo, T | 1 |
| Satoh, T | 5 |
| Uemura, M | 1 |
| Matsuda, C | 3 |
| Mizushima, T | 2 |
| Murata, K | 2 |
| Doki, Y | 2 |
| Eguchi, H | 1 |
| Kwakman, JJM | 3 |
| Simkens, LHJ | 2 |
| van Rooijen, JM | 2 |
| van de Wouw, AJ | 1 |
| Ten Tije, AJ | 1 |
| Creemers, GJM | 1 |
| Hendriks, MP | 2 |
| Los, M | 2 |
| van Alphen, RJ | 2 |
| Polée, MB | 2 |
| Muller, EW | 2 |
| van der Velden, AMT | 2 |
| van Voorthuizen, T | 2 |
| Koopman, M | 3 |
| Mol, L | 2 |
| van Werkhoven, E | 2 |
| Punt, CJA | 3 |
| Mukai, T | 1 |
| Uehara, K | 4 |
| Goto, H | 2 |
| Hiramatsu, K | 3 |
| Kobayashi, S | 3 |
| Sakamoto, E | 3 |
| Maeda, A | 4 |
| Takeuchi, E | 3 |
| Okada, Y | 2 |
| Ebata, T | 2 |
| Nagino, M | 4 |
| Franck, C | 1 |
| Malfertheiner, P | 1 |
| Venerito, M | 1 |
| Baars, A | 1 |
| van Zweeden, AA | 1 |
| de Mol, P | 1 |
| Kok, WEM | 1 |
| Li, J | 2 |
| Xu, R | 1 |
| Xu, J | 2 |
| Ikejiri, K | 1 |
| Shen, L | 2 |
| Toh, Y | 2 |
| Kato, T | 10 |
| Sakai, K | 2 |
| Yamamoto, M | 3 |
| Mishima, H | 5 |
| Wang, J | 2 |
| Kusumoto, T | 1 |
| Sunami, E | 1 |
| Ota, M | 1 |
| Yoshida, K | 5 |
| Sakamoto, Y | 4 |
| Mochizuki, I | 1 |
| Okabe, M | 1 |
| Kunieda, K | 1 |
| Yamauchi, J | 1 |
| Itabashi, M | 1 |
| Kotake, K | 1 |
| Takahashi, K | 3 |
| Boku, N | 8 |
| Aiba, K | 3 |
| Ishiguro, M | 2 |
| Sugihara, K | 6 |
| Shimodaira, H | 2 |
| Kobayashi, K | 4 |
| Miyamoto, Y | 5 |
| Naito, M | 1 |
| Chino, S | 1 |
| Ushiku, H | 1 |
| Nishi, Y | 1 |
| Kondo, Y | 1 |
| Kubo, H | 1 |
| Kaida, T | 1 |
| Yamashita, W | 1 |
| Takahashi, Y | 3 |
| Watanabe, M | 12 |
| Honda, M | 2 |
| Tanaka, C | 3 |
| Kondo, K | 1 |
| Takahashi, T | 4 |
| Kosugi, C | 2 |
| Takemoto, H | 2 |
| Kim, HM | 1 |
| Sakamoto, J | 2 |
| Oba, K | 2 |
| Chen, Y | 1 |
| Wu, J | 1 |
| Cheng, K | 1 |
| Li, ZP | 1 |
| Luo, DY | 2 |
| Qiu, M | 1 |
| Gou, HF | 1 |
| Yi, C | 1 |
| Li, Q | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Cao, D | 1 |
| Shen, YL | 1 |
| Bi, F | 1 |
| Liu, JY | 1 |
| Tanioka, H | 2 |
| Morita, Y | 1 |
| Ishibashi, K | 1 |
| Kataoka, M | 1 |
| Satake, H | 1 |
| Munemoto, Y | 1 |
| van de Wouw, YAJ | 1 |
| Tije, AJT | 1 |
| Creemers, GM | 1 |
| Moriwaki, T | 2 |
| Sakai, Y | 1 |
| Ishida, H | 2 |
| Yamamoto, Y | 1 |
| Endo, S | 1 |
| Kuramochi, H | 5 |
| Sato, M | 1 |
| Hatachi, Y | 1 |
| Bando, Y | 1 |
| Maeba, T | 1 |
| Ikezawa, K | 1 |
| Shimada, M | 2 |
| Amagai, K | 1 |
| Morimoto, M | 1 |
| Tsuji, A | 8 |
| Nishina, T | 7 |
| Hyodo, I | 7 |
| Chen, J | 1 |
| Xu, T | 1 |
| Hata, T | 1 |
| Fukunaga, M | 3 |
| Uemura, Y | 1 |
| Fukuzaki, T | 1 |
| Ota, H | 1 |
| Ohue, M | 1 |
| Ohnishi, T | 1 |
| Tanaka, N | 1 |
| Takemasa, I | 1 |
| Ikeda, M | 1 |
| Yamamoto, H | 1 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Mori, M | 1 |
| Neki, K | 1 |
| Kawahara, H | 5 |
| Watanabe, K | 5 |
| Toyama, Y | 4 |
| Akiba, T | 4 |
| Yanaga, K | 7 |
| Kim, SY | 6 |
| S Hong, Y | 1 |
| K Shim, E | 1 |
| Kong, SY | 2 |
| Shin, A | 1 |
| Baek, JY | 3 |
| Jung, KH | 3 |
| Park, SR | 2 |
| Hong, YS | 6 |
| Lim, HS | 1 |
| Seong, MW | 1 |
| Park, YI | 1 |
| Enomoto, H | 3 |
| Takahari, D | 5 |
| Matsumoto, H | 5 |
| Yoshida, M | 5 |
| Iwamoto, S | 1 |
| Sasaki, Y | 4 |
| Sakata, Y | 7 |
| Shimada, Y | 9 |
| Nakamura, H | 1 |
| Doi, Y | 3 |
| Abu Lila, AS | 4 |
| Nagao, A | 2 |
| Ishida, T | 5 |
| Kiwada, H | 4 |
| Tomoda, M | 1 |
| Lee, J | 5 |
| Shin, SJ | 5 |
| Chung, IJ | 3 |
| Kim, TW | 6 |
| Chun, HG | 1 |
| Shin, DB | 3 |
| Kim, YH | 2 |
| Song, HS | 1 |
| Han, SW | 2 |
| Kim, JG | 1 |
| Choi, YJ | 1 |
| Chung, HC | 3 |
| Komura, T | 1 |
| Miura, K | 1 |
| Shirasaka, T | 6 |
| Ohnuma, S | 1 |
| Kajiwara, T | 1 |
| Fujishima, F | 1 |
| Philchenkov, A | 1 |
| Nakagawa, K | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shibata, C | 1 |
| Unno, M | 1 |
| Takii, Y | 1 |
| Yamazaki, T | 1 |
| Okada, T | 3 |
| Tani, T | 1 |
| Funakoshi, K | 1 |
| Maruyama, S | 1 |
| Hasegawa, J | 1 |
| Akazawa, K | 1 |
| Hatakeyama, K | 1 |
| Yoshida, N | 1 |
| Higashi, D | 1 |
| Egawa, Y | 1 |
| Hirano, Y | 1 |
| Hirano, K | 1 |
| Miyake, T | 1 |
| Takahashi, H | 1 |
| Uwatoko, S | 1 |
| Abe, S | 1 |
| Yamamoto, S | 1 |
| Mikami, K | 1 |
| Futami, K | 2 |
| Maekawa, T | 1 |
| Inoue, R | 1 |
| Miyazaki, M | 1 |
| Yasui, H | 4 |
| Sameshima, S | 2 |
| Ina, K | 3 |
| Yamaguchi, K | 4 |
| Esaki, T | 6 |
| Tokunaga, S | 3 |
| Kuwano, H | 3 |
| Hong, L | 1 |
| Guo, Z | 1 |
| Yu, H | 1 |
| Li, B | 1 |
| Si, T | 1 |
| Liu, C | 1 |
| Kim, ST | 1 |
| Lim, HY | 4 |
| Kim, KP | 3 |
| Kim, JH | 3 |
| Lee, KW | 2 |
| Cho, SH | 2 |
| Lee, KH | 3 |
| Kang, HJ | 2 |
| Lee, JW | 2 |
| Jo, SJ | 2 |
| Park, YS | 5 |
| Yamazaki, K | 6 |
| Ojima, H | 1 |
| Otsuji, T | 1 |
| Shirao, K | 6 |
| Ohishi, T | 1 |
| Takeuchi, M | 1 |
| Tanaka, A | 1 |
| Kamijo, A | 1 |
| Maruo, H | 1 |
| Suzuki, K | 1 |
| Ishikawa, S | 1 |
| Murakami, T | 1 |
| Higashi, Y | 1 |
| Shoji, T | 1 |
| Yamazaki, M | 1 |
| Taniguchi, M | 1 |
| Nishiyama, R | 1 |
| Hamamoto, Y | 1 |
| Yoshino, T | 4 |
| Miyata, Y | 3 |
| Ohtsu, A | 4 |
| Tojima, Y | 2 |
| Yatsuya, H | 1 |
| Lu, M | 1 |
| Wang, Y | 1 |
| Liu, W | 1 |
| Bai, C | 1 |
| Morimoto, T | 1 |
| Yata, Y | 1 |
| Yonenaga, Y | 1 |
| Hanaki, K | 1 |
| Mise, M | 1 |
| Higaside, S | 1 |
| Kanda, Y | 1 |
| Noda, H | 1 |
| Iwasa, S | 2 |
| Nagashima, K | 1 |
| Ichikawa, Y | 2 |
| Goto, A | 6 |
| Kato, K | 6 |
| Okita, NT | 2 |
| Nitta, S | 1 |
| Nomura, M | 1 |
| Andoh, M | 1 |
| Mori, K | 1 |
| Igarashi, Y | 1 |
| Oki, E | 3 |
| Emi, Y | 3 |
| Kabashima, A | 1 |
| Higashi, H | 1 |
| Ogata, Y | 5 |
| Ikebe, M | 1 |
| Saeki, H | 2 |
| Shirabe, K | 1 |
| Beppu, T | 2 |
| Uchida, S | 1 |
| Takatsuki, M | 1 |
| Sakoda, M | 1 |
| Eguchi, S | 1 |
| Akagi, Y | 4 |
| Kakeji, Y | 1 |
| Natsugoe, S | 3 |
| Maehara, Y | 3 |
| Goto, R | 1 |
| Kurihara, M | 1 |
| Wang, ZQ | 1 |
| Zhang, DS | 1 |
| Xu, N | 1 |
| Deng, YH | 1 |
| Wang, FH | 1 |
| Luo, HY | 1 |
| Qiu, MZ | 1 |
| Li, YH | 1 |
| Xu, RH | 1 |
| Maekawa, S | 1 |
| Kawanaka, H | 1 |
| Kitazono, M | 1 |
| Murakami, H | 1 |
| Shimokawa, M | 2 |
| Ishikawa, T | 1 |
| Uetake, H | 1 |
| Murotani, K | 1 |
| Kobunai, T | 2 |
| Matsui, S | 1 |
| Yamauchi, K | 1 |
| Kokuryo, T | 1 |
| Yokoyama, Y | 1 |
| Yamaguchi, J | 1 |
| Ogawa, M | 2 |
| Anan, T | 2 |
| Okuma, M | 1 |
| Ichihara, K | 1 |
| Hasegawa, T | 1 |
| Hasegawa, K | 2 |
| Oba, M | 1 |
| Saiura, A | 1 |
| Arita, J | 1 |
| Shinozaki, E | 1 |
| Mizunuma, N | 1 |
| Matsuyama, Y | 1 |
| Kokudo, N | 1 |
| Winther, SB | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Jensen, HA | 1 |
| Krogh, M | 1 |
| Sorbye, H | 1 |
| Pfeiffer, P | 1 |
| Takagane, A | 1 |
| Miyake, Y | 2 |
| Nagata, N | 1 |
| Otsuka, K | 2 |
| Kagimura, T | 1 |
| Takaoka, T | 1 |
| Kimura, T | 1 |
| Shimoyama, R | 1 |
| Kawamoto, S | 1 |
| Sakamoto, K | 2 |
| Goda, F | 1 |
| Miyamoto, H | 1 |
| Negoro, Y | 1 |
| Yoshizaki, K | 1 |
| Goji, T | 1 |
| Kitamura, S | 1 |
| Yano, H | 1 |
| Okamoto, K | 1 |
| Kimura, M | 1 |
| Okahisa, T | 1 |
| Muguruma, N | 1 |
| Niitsu, Y | 1 |
| Takayama, T | 1 |
| Nozawa, H | 1 |
| Ishihara, S | 1 |
| Kawai, K | 1 |
| Murono, K | 1 |
| Yasuda, K | 1 |
| Otani, K | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 2 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Watanabe, T | 3 |
| Koda, K | 1 |
| Miyauchi, H | 1 |
| Kaiho, T | 1 |
| Takiguchi, N | 1 |
| Maruyama, T | 1 |
| Matsubara, H | 1 |
| Moriyoshi, N | 1 |
| Fukushima, M | 6 |
| Huang, CL | 2 |
| Wada, H | 2 |
| Narahara, H | 1 |
| Sugimoto, N | 1 |
| Yoshisue, K | 1 |
| Yin, J | 1 |
| Zhu, X | 1 |
| Liu, Y | 1 |
| Cao, J | 1 |
| Lu, F | 1 |
| Zuo, Y | 1 |
| Kim, BC | 1 |
| Park, JW | 1 |
| Choi, HS | 1 |
| Jeong, SY | 1 |
| Kim, DY | 1 |
| Hong, CW | 1 |
| Sohn, DK | 1 |
| Shiozawa, M | 2 |
| Sugano, N | 2 |
| Tsuchida, K | 2 |
| Morinaga, S | 2 |
| Akaike, M | 2 |
| Sugimasa, Y | 1 |
| Yoshimatsu, K | 1 |
| Yokomizo, H | 1 |
| Osawa, G | 1 |
| Fujimoto, T | 1 |
| Otani, T | 1 |
| Tsunoda, T | 2 |
| Nakamura, Y | 2 |
| Ogawa, K | 1 |
| Zang, DY | 2 |
| Lee, BH | 1 |
| Park, HC | 1 |
| Song, HH | 1 |
| Kim, HJ | 1 |
| Jung, JY | 1 |
| Kim, HY | 1 |
| Kwon, JH | 1 |
| Hwang, SW | 1 |
| Park, CH | 1 |
| Kim, KO | 1 |
| Kim, MJ | 1 |
| Jang, KM | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Fukutomi, A | 1 |
| Taku, K | 1 |
| Kojima, T | 1 |
| Machida, N | 1 |
| Yokoo, K | 2 |
| Hamada, A | 2 |
| Tazoe, K | 1 |
| Saito, H | 3 |
| Watanabe, Y | 1 |
| Furukawa, H | 1 |
| Hirashima, Y | 1 |
| Matsubara, J | 1 |
| Hamaguchi, T | 4 |
| Shimoda, T | 1 |
| Kim, HS | 2 |
| Park, MJ | 1 |
| Uhm, JE | 1 |
| Lee, Y | 1 |
| Lee, HY | 2 |
| Kang, EM | 1 |
| Park, SH | 2 |
| Park, JO | 2 |
| Kang, WK | 2 |
| Tsunoda, A | 4 |
| Yasuda, N | 3 |
| Nakao, K | 4 |
| Narita, K | 4 |
| Matsui, N | 2 |
| Kusano, M | 4 |
| Hibi, S | 1 |
| Furuta, R | 1 |
| Kataoka, T | 1 |
| Kojima, S | 1 |
| Kawai, M | 1 |
| Koizumi, W | 1 |
| Sawaki, A | 1 |
| Furuhata, T | 1 |
| Miyashita, K | 1 |
| Yoshioka, T | 1 |
| Kato, S | 2 |
| Chiba, N | 1 |
| Sakayori, N | 1 |
| Shibata, H | 1 |
| Kakudo, Y | 1 |
| Hiraki, M | 1 |
| Kitajima, Y | 1 |
| Nakafusa, Y | 1 |
| Nakamura, J | 1 |
| Hashiguchi, K | 1 |
| Sumi, K | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Sasatomi, T | 1 |
| Ishibashi, N | 1 |
| Mori, S | 1 |
| Shirouzu, K | 1 |
| Tsunoda, Y | 1 |
| Oh, SY | 1 |
| Ju, YT | 1 |
| Choi, SK | 1 |
| Ha, CY | 1 |
| Lee, WS | 1 |
| Kim, HG | 1 |
| Lee, GW | 1 |
| Kwon, HC | 1 |
| Kang, JH | 1 |
| Jeong, JH | 1 |
| Shim, BY | 1 |
| Oh, DY | 2 |
| Lee, MA | 1 |
| Kim, YT | 1 |
| Roh, JK | 3 |
| Ahn, JB | 3 |
| Yagi, M | 1 |
| Watanabe, S | 1 |
| Yoshino, S | 1 |
| Hazama, S | 1 |
| Suga, T | 1 |
| Nakazawa, S | 1 |
| Yamamoto, N | 1 |
| Takiuchi, H | 2 |
| Ichihara, M | 2 |
| Hong, J | 1 |
| Ham, HS | 1 |
| Kim, TY | 2 |
| Choi, IS | 1 |
| Kim, BS | 1 |
| Im, SA | 1 |
| Kang, GH | 1 |
| Bang, YJ | 1 |
| Schmoll, HJ | 1 |
| Kusaba, H | 2 |
| Tanaka, S | 1 |
| Fujishima, H | 1 |
| Mitsugi, K | 2 |
| Ariyama, H | 1 |
| Tanaka, R | 1 |
| Kinugawa, N | 1 |
| Ueki, T | 1 |
| Mibu, R | 1 |
| Baba, E | 2 |
| Nakano, S | 1 |
| Akashi, K | 2 |
| Lee, DJ | 1 |
| Lim, T | 1 |
| Lee, SJ | 1 |
| Yi, SY | 1 |
| Molina-Garrido, MJ | 1 |
| Guillén-Ponce, C | 1 |
| Kadota, K | 1 |
| Liu, D | 1 |
| Yokomise, H | 1 |
| Haba, R | 1 |
| Shitara, K | 1 |
| Utsunomiya, S | 1 |
| Yokota, T | 1 |
| Sato, Y | 2 |
| Inaba, Y | 2 |
| Tajika, M | 1 |
| Kawai, H | 1 |
| Yamaura, H | 2 |
| Kato, M | 1 |
| Kaneko, J | 1 |
| Isogai, J | 1 |
| Aoyagi, H | 1 |
| Katsuta, E | 1 |
| Someno, Y | 1 |
| Saguchi, M | 1 |
| Takahata, T | 1 |
| Hamada, S | 1 |
| Maejima, S | 1 |
| Choi, YH | 2 |
| Lee, SS | 2 |
| Ryu, MH | 2 |
| Lee, JL | 2 |
| Chang, HM | 2 |
| Kang, YK | 2 |
| Sogabe, S | 3 |
| Kusumi, T | 1 |
| Hatanaka, K | 2 |
| Miyagishima, T | 3 |
| Hosokawa, A | 2 |
| Asaka, M | 4 |
| Nakayama, G | 1 |
| Kodera, Y | 1 |
| Yokoyama, H | 1 |
| Okuda, N | 1 |
| Iwata, N | 1 |
| Ohashi, N | 1 |
| Koike, M | 1 |
| Fujiwara, M | 1 |
| Nakao, A | 1 |
| Jung, M | 1 |
| Jeung, HC | 2 |
| Kim, HR | 1 |
| Rha, SY | 3 |
| Fukushima, H | 2 |
| Kudo, M | 4 |
| Tateyama, M | 4 |
| Meguro, T | 3 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Sasaki, H | 1 |
| Matsueda, S | 1 |
| Yanagisawa, S | 1 |
| Nakatsumi, H | 1 |
| Munakata, M | 1 |
| Ryoo, BY | 1 |
| Shin, JG | 1 |
| Kobayashi, T | 1 |
| Eto, K | 1 |
| Oda, A | 1 |
| Hayashi, T | 1 |
| Mitsuyama, Y | 1 |
| Nukatsuka, M | 2 |
| Nakagawa, F | 2 |
| Uchida, J | 3 |
| Shiraishi, K | 1 |
| Takechi, T | 1 |
| Sakaguchi, K | 1 |
| Honma, Y | 1 |
| Grothey, A | 1 |
| Okabe, H | 1 |
| Baba, Y | 1 |
| Iwatsuki, M | 1 |
| Chikamoto, A | 1 |
| Kishimoto, J | 1 |
| Uchino, K | 1 |
| Arita, S | 1 |
| Kumagai, H | 1 |
| Goto, M | 1 |
| Kii, T | 1 |
| Nishitani, H | 1 |
| Kawabe, S | 2 |
| Kuwakado, S | 1 |
| Asaishi, K | 1 |
| Miyamoto, T | 1 |
| Higuchi, K | 1 |
| Eng, C | 1 |
| Kindler, HL | 1 |
| Schilsky, RL | 1 |
| Gotoh, M | 1 |
| Ohta, S | 1 |
| Katsu, K | 1 |
| Van den Brande, J | 1 |
| Schöffski, P | 1 |
| Schellens, JH | 1 |
| Roth, AD | 1 |
| Duffaud, F | 1 |
| Weigang-Köhler, K | 1 |
| Reinke, F | 1 |
| Wanders, J | 1 |
| de Boer, RF | 1 |
| Vermorken, JB | 1 |
| Fumoleau, P | 1 |
| Hoff, PM | 3 |
| Taguchi, S | 1 |
| Doi, T | 1 |
| Uchida, K | 4 |
| Hayashi, K | 4 |
| Kawakami, K | 1 |
| Schneider, S | 2 |
| Yochim, JM | 2 |
| Takasaki, K | 2 |
| Danenberg, KD | 3 |
| Danenberg, PV | 3 |
| Takada, H | 1 |
| Mitachi, Y | 2 |
| Hirakawa, K | 1 |
| Horikoshi, N | 3 |
| Okamura, T | 1 |
| Hirata, K | 2 |
| Saitoh, S | 1 |
| Isomoto, H | 1 |
| Satoh, A | 1 |
| Chu, QS | 1 |
| Hammond, LA | 1 |
| Schwartz, G | 1 |
| Ochoa, L | 1 |
| Denis, L | 1 |
| Molpus, K | 1 |
| Roedig, B | 1 |
| Letrent, SP | 1 |
| Damle, B | 1 |
| DeCillis, AP | 1 |
| Rowinsky, EK | 1 |
| Mushiake, H | 1 |
| Shimao, K | 1 |
| Tahara, H | 1 |
| Yuuki, S | 1 |
| Fuse, N | 1 |
| Takei, M | 1 |
| Kunieda, Y | 1 |
| Wakahama, O | 1 |
| Ohizumi, H | 1 |
| Akita, H | 1 |
| Nakano, K | 1 |
| Koizumi, H | 1 |
| Okugawa, K | 1 |
| Nakamura, K | 1 |
| Osaka, Y | 1 |
| Tsuchiya, K | 1 |
| Sako, H | 1 |
| Tanabe, S | 1 |
| Nakane, Y | 1 |
| Yang, D | 1 |
| Kabeshima, Y | 1 |
| Kameyama, N | 1 |
| Toizumi, A | 1 |
| Tamura, Y | 1 |
| Kageyama, T | 1 |
| Nakata, E | 1 |
| Takai, Y | 1 |
| Nemoto, K | 1 |
| Ogawa, Y | 1 |
| Nomiya, T | 1 |
| Milas, L | 1 |
| Yamada, S | 1 |
| Eguchi, T | 1 |
| Kamiyama, G | 1 |
| Suzuki, N | 2 |
| Oonaka, T | 1 |
| Arai, Y | 1 |
| Takeuchi, Y | 1 |
| Aramaki, T | 1 |
| Seki, H | 1 |
| Matsueda, K | 1 |
| Watanabe, H | 1 |
| Masa, K | 1 |
| Terazaki, H | 1 |
| Cho, BC | 1 |
| Yoo, NC | 1 |
| Roh, WJ | 1 |
| Tsujimoto, H | 1 |
| Tsukioka, S | 1 |
| Koizumi, K | 1 |
| Sugimoto, Y | 1 |
| Oka, T | 1 |
| Ogata, K | 1 |
| Ohchi, T | 1 |
| Doi, K | 1 |
| Matsuo, A | 1 |
| Kudo, K | 1 |
| Ootao, R | 1 |
| Nakajima, G | 2 |
| Inoue, Y | 1 |
| Hatori, T | 1 |
| Nomura, H | 1 |
| Murakami, Y | 1 |
| Shimamoto, Y | 1 |
| Yonekura, R | 1 |
| Ohshimo, H | 1 |
| Cao, S | 1 |
| Lu, K | 1 |
| Tóth, K | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Brito, RA | 1 |
| Medgyesy, D | 2 |
| Zukowski, TH | 1 |
| Royce, ME | 1 |
| Ravandi-Kashani, F | 1 |
| Pazdur, R | 2 |
| Okazaki, M | 1 |
| Denno, R | 1 |
| Sasaki, K | 1 |
| Nakano, Y | 1 |
| Ishizuka, H | 1 |
| Uno, S | 1 |
| Taguchi, T | 3 |
| Royce, M | 1 |
| Brito, R | 1 |
| Sugimachi, K | 1 |
| Van Cutsem, E | 1 |
| Peeters, M | 1 |
| Sasaki, T | 1 |
| Maeda, Y | 1 |
| Tsukuda, M | 1 |
| Inuyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines[NCT01918852] | Phase 3 | 161 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258] | Phase 2/Phase 3 | 426 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443] | Phase 3 | 344 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer[NCT01110941] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized Phase II Study of Oxaliplatin and S-1 (SOX) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Peritoneal Metastasis of Colorectal Cancer[NCT02870153] | Phase 2 | 60 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790] | Phase 2 | 53 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for oxonic acid and Colorectal Cancer
| Article | Year |
|---|---|
Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Sur | 2019 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2014 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2001 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
[Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2005 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug | 2006 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Tria | 2000 |
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal | 2001 |
91 trials available for oxonic acid and Colorectal Cancer
| Article | Year |
|---|---|
Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study).
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Fem | 2019 |
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Topics: Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Humans; Maintenance Chemotherapy; Ne | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2020 |
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2020 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2021 |
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Oxonic Acid; Tega | 2017 |
Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2018 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; D | 2018 |
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Me | 2019 |
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2019 |
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2019 |
Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2013 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptoth | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydro | 2013 |
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colore | 2014 |
Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2013 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2015 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ | 2014 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2015 |
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease- | 2015 |
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2015 |
A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2015 |
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2015 |
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Combinations; | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2016 |
Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemot | 2016 |
Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug C | 2016 |
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2016 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan | 2016 |
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2017 |
Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Femal | 2008 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2009 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2009 |
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neop | 2008 |
Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2009 |
A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2009 |
Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2009 |
Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2011 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2011 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2011 |
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Re | 2012 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2012 |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptoth | 2012 |
Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2013 |
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 2013 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male | 2003 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2004 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2004 |
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combi | 2005 |
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cyclooxygenase 2; Drug Combinations; Fe | 2005 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal | 2006 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2006 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2008 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinati | 1999 |
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combi | 2000 |
51 other studies available for oxonic acid and Colorectal Cancer
| Article | Year |
|---|---|
Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report.
Topics: Aged; Asian People; Biopsy; Colorectal Neoplasms; Creatinine; Diabetic Nephropathies; Disease Progre | 2020 |
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2017 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Co | 2017 |
[Chemoradiotherapy with S-1 for Recurrence Cases of Colorectal Cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Colorectal Neoplasms; Disease Progression; Drug | 2018 |
Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Administrati | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
[Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Hum | 2014 |
[Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
[Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug Combination | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; C | 2017 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; D | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2009 |
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Island | 2010 |
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Oxonic Acid; Tegafur | 2011 |
[Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Digestive System Neoplas | 2010 |
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2010 |
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com | 2010 |
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Follow-U | 2011 |
Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer".
Topics: Aged; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dru | 2011 |
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolifera | 2011 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy P | 2012 |
Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D | 2012 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2012 |
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplas | 2013 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplati | 2002 |
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA | 2004 |
Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combi | 2005 |
[Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2005 |
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplas | 2006 |
Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 2006 |
[Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Models, | 2007 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2007 |
Combination therapy of S-1 and CDDP for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2007 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; | 1998 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin | 1999 |